Portfolio de James Altucher

• ScanSource SCSC 10/20/2016 $38
• Hertz HTZ 9/15/2016 $53
• Advaxis ADXS 8/18/2016 $15
• Vuzix VUZI 7/21/2016 $8.25
• Illumina ILMN 6/16/2016 $147
• Hortonworks *** 5/19/2016 $11.25
• Kinder Morgan KMI 4/21/2016 $19
• Teva Pharmaceutical TEVA 3/17/2016 $58
• Navient NAVI 2/18/2016 $11
• Remark Media MARK 12/17/2015 $6
• AerCap AER 11/19/2015 $45
• Dycom DY 10/14/2015 $80
• LSB Industries LXU 9/29/2015 $20
• Howard Hughes Corp. HHC 9/16/2015 $140
• Clean Harbors CLH 09/11/2015 $50
• Flex International FLEX 09/10/2015 $10

Los precio són precios de compra recomendados, y la fecha es la fecha de Tienen tres criterios:
1) apoyados en una megatendencia: medicina personalizada; big data; realidad virtual...
2) empresas coinvertidas por gente que sabe mucho como Buffet.
3) precio de compra barato, con respecto a una valoración fundamental

---------- Post added 02-dic-2016 at 13:20 ----------

Hertz Global Holdings ( NYSE: htz )
Positives:
»
Hertz recently partnered with Uber and Lyft to get in on the ride-sharing
trend.
»
At the urging of billionaire investor Carl Icahn, the company brought in
a new all-star management team with a history of turning around struggling businesses.
»
Several members of the new team including the CEO, CFO and CIO are buying up shares, and institutional investors are also establishing large positions.
»
Management plans on cutting up to $950M in expenses through 2020, which could help grow earnings by 25%.
»
Hertz saved more than $2B by restructuring its debt, and it plans to
use some of that cash to buy back to $1B worth of its shares.

Risk Factors:
»
More travelers are using ride-sharing platforms for airport rides, which
is how car rental companies typically generate the most revenue. Hertz
generates about 75% of its U.S. sales from airport operations. But most
of this risk is factored into shares
with the stock down 40%-plus from its
highs.
»
Though the company is reinventing itself, historically these kinds of transitions can present major challenges, resulting in lower stock prices
as investors lose patience.
»
Over the past two years, the company share price has dropped by 40%.

2
hertz Global holdings (continued )
Investment Synopsis:
»
Buy-up-to price: $53 per share
Fair value: Fair market value is $65 per share.
Exit strategy: Hold for at least 24 months. This is when the stock is likely to see its greatest gains come to fruition.
Position size: 2%-3% of total portfolio

Hertz Global Holdings, Inc. (HTZ) -NYSE
24,38

teva pharmaceuticals (NYSE: TEVA)
Positives:
»
The generic pharmaceuticals industry
is a multi-billion dollar market with
infinite growth potential.
»
Teva is the world’s biggest generic
drug maker and is in position to
dominate the space.
»
Teva has never been this cheap in its
history as a public company.
»
The company has huge growth
catalysts ahead as it completes its
upcoming merger with Allergan’s
generic business.
»
It was one of the top-bought stocks
by the 50 largest hedge funds last
quarter.
Risk Factors:
»
Pipeline failures. Expected new ge
-
neric drugs may either not work out
as expected or may not be as profit
-
able as expected.
»
Larger-than-expected revenue loss
from the drug Copaxone.
»
New legislation could be passed to
more tightly regulate generics.
Investment Synopsis:
»
Buy-up-to Price: $
58
»
Exit strategy: I expect this to
be a
co
re
ho
lding for the portfolio, so I wi
ll
only
sell half when we’re up 100%
and will
re-evaluate the position if it
falls
more than 25%.
»
Position size: 4-5% of portfolio

Estado del portfolio


Alcoa se descarta pues la empresa ya se ha divido en Arconic y Alcoa Stream

Advaxis

advaxis ( nasdaq: ADXS )
Positives:
»
Advaxis has access to potentially
game-changing medical technology
»
It has partnered with Amgen on the
development and commercialization
of its preclinical ADXS-NEO immu-
notherapy treatment, paying ADXS
$40M up front and up to $475M
going forward
»
Amgen also owns 5% of the company
»
AstraZeneca and Incyte have an-
nounced partnerships with Advaxis
to develop ADXS-HPV alongside their
own immunotherapy platforms
»
The company has also partnered
with Merck, Stendhal and academic
institution
s
including Brown Univer-
sity, Children’s Oncology Group and
Memorial Sloan Kettering
»
It
h
as one of the best platforms
in
the
immunotherapy space, and the
market to treat cancer is worth more
than $100 billion
Risk Factors:
»
Advaxis is an early-stage biotech
company, which is a generally risky
sector to begin with
»
If its trial results are not positive
,
the
stock could easily fall 25% or more
from these levels
»
If its numerous trials get delayed
for
any reason, Adv
axis may have to
raise more cash, which would dilute
current shareholders. This could also
result in a huge pullback in the stock
August 2016 - Top 1% Advisory
visit:
2
advaxis (continued )
Investment Synopsis:
»
Buy-up-to price: $15
»
Fair value per share: $30
»
Position size: 3% of total portfolio
»
Exit strategy: Once it hits fair value,
I suggest selling half the position
and letting the other half ride for the
long term